Payment overview · 2025
General Payments
$421.88
23 reported records · 10 companies
Healthcare provider profile · identity verified
Dipesh Ratilal Patel, MD
Allopathic & Osteopathic Physicians|Family Medicine · MACON, GA · NPI 1700985454
Verified facts
What the public records show
CMS Open Payments records show Dipesh Ratilal Patel, MD received $421.88 in general payments during 2025 across 23 reported records.
ABBVIE INC. accounted for 24.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 717 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $103.74 | 24.6% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $95.18 | 22.6% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $61.12 | 14.5% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $40.52 | 9.6% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $34.90 | 8.3% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.04 | 4.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.97 | 4.3% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $16.95 | 4.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.34 | 3.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.12 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $421.88 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $68.30 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $59.77 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $46.00 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $39.07 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $35.44 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $35.44 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $35.41 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $34.90 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $29.92 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $23.40 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.40 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $20.04 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $17.97 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $16.95 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 717 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 149 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
149 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
717 | 67 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1476 | 219 |
| Amlodipine Besylate | Amlodipine Besylate | 1432 | 177 |
| Potassium Chloride | Potassium Chloride | 1012 | 111 |
| Levothyroxine Sodium | Levothyroxine Sodium | 902 | 110 |
| Pravastatin Sodium | Pravastatin Sodium | 886 | 85 |
| Gabapentin | Gabapentin | 872 | 118 |
| Furosemide | Furosemide | 784 | 99 |
| Famotidine | Famotidine | 781 | 105 |
| Eliquis | Apixaban | 717 | 67 |
| Omeprazole | Omeprazole | 627 | 126 |
| Metoprolol Tartrate | Metoprolol Tartrate | 602 | 85 |
| Levetiracetam | Levetiracetam | 573 | 21 |
| Carvedilol | Carvedilol | 565 | 64 |
| Valsartan | Valsartan | 527 | 46 |
| Sertraline Hcl | Sertraline Hcl | 506 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 486 | 72 |
| Pantoprazole Sodium | Pantoprazole Sodium | 465 | 85 |
| Mirtazapine | Mirtazapine | 428 | 57 |
| Clopidogrel | Clopidogrel Bisulfate | 425 | 66 |
| Escitalopram Oxalate | Escitalopram Oxalate | 414 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 405 | 36 |
| Hydralazine Hcl | Hydralazine Hcl | 398 | 43 |
| Metformin Hcl | Metformin Hcl | 386 | 93 |
| Losartan Potassium | Losartan Potassium | 375 | 94 |
| Memantine Hcl | Memantine Hcl | 348 | 27 |
| Allopurinol | Allopurinol | 341 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 325 | 56 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 306 | 80 |
| Glipizide | Glipizide | 302 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 301 | 54 |
| Lisinopril | Lisinopril | 287 | 60 |
| Trazodone Hcl | Trazodone Hcl | 285 | 32 |
| Nifedipine Er | Nifedipine | 263 | 16 |
| Buspirone Hcl | Buspirone Hcl | 234 | 18 |
| Montelukast Sodium | Montelukast Sodium | 222 | 38 |
| Risperidone | Risperidone | 210 | suppressed |
| Glipizide Er | Glipizide | 203 | 58 |
| Quetiapine Fumarate | Quetiapine Fumarate | 202 | 17 |
| Azithromycin | Azithromycin | 201 | 142 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 198 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 177 | 91 |
| Aripiprazole | Aripiprazole | 174 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 173 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 170 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 170 | 42 |
| Tradjenta | Linagliptin | 169 | 13 |
| Prednisone | Prednisone | 167 | 100 |
| Spironolactone | Spironolactone | 164 | 22 |
| Januvia | Sitagliptin Phosphate | 154 | 39 |
| Ozempic | Semaglutide | 149 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 143 | 69 |
| Finasteride | Finasteride | 143 | 22 |
| Donepezil Hcl | Donepezil Hcl | 132 | 15 |
| Tramadol Hcl | Tramadol Hcl | 132 | 59 |
| Sevelamer Carbonate | Sevelamer Carbonate | 128 | suppressed |
| Simvastatin | Simvastatin | 127 | 40 |
| Jardiance | Empagliflozin | 124 | 23 |
| Divalproex Sodium | Divalproex Sodium | 120 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 120 | suppressed |
| Xarelto | Rivaroxaban | 118 | 15 |
| Sucralfate | Sucralfate | 117 | 20 |
| Entresto | Sacubitril/Valsartan | 112 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 111 | 19 |
| Ezetimibe | Ezetimibe | 110 | 12 |
| Olanzapine | Olanzapine | 105 | suppressed |
| Bumetanide | Bumetanide | 104 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 103 | 14 |
| Alprazolam | Alprazolam | 101 | 37 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 100 | 24 |
| Glimepiride | Glimepiride | 96 | 15 |
| Lactulose | Lactulose | 96 | 33 |
| Baclofen | Baclofen | 94 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 93 | 20 |
| Torsemide | Torsemide | 88 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 88 | suppressed |
| Levemir Flexpen | Insulin Detemir | 87 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 87 | 32 |
| Doxazosin Mesylate | Doxazosin Mesylate | 84 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 82 | 13 |
| Pregabalin | Pregabalin | 81 | 15 |
| Amoxicillin | Amoxicillin | 76 | 67 |
| Mounjaro | Tirzepatide | 74 | 14 |
| Labetalol Hcl | Labetalol Hcl | 72 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 70 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 70 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 66 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 65 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 65 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 63 | 38 |
| Doxycycline Hyclate | Doxycycline Hyclate | 62 | 47 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 62 | 46 |
| Bupropion Xl | Bupropion Hcl | 61 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 61 | 32 |
| Propranolol Hcl | Propranolol Hcl | 60 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 60 | 30 |
| Midodrine Hcl | Midodrine Hcl | 59 | suppressed |
| Atenolol | Atenolol | 58 | 17 |
| Brilinta | Ticagrelor | 58 | suppressed |
| Latanoprost | Latanoprost | 58 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 58 | 46 |
| Paroxetine Hcl | Paroxetine Hcl | 58 | suppressed |
| Topiramate | Topiramate | 57 | suppressed |
| Fluconazole | Fluconazole | 56 | 36 |
| Ropinirole Hcl | Ropinirole Hcl | 56 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 55 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 55 | suppressed |
| Celecoxib | Celecoxib | 54 | 22 |
| Cephalexin | Cephalexin | 54 | 40 |
| Lamotrigine | Lamotrigine | 54 | suppressed |
| Nadolol | Nadolol | 54 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 54 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 53 | suppressed |
| Armour Thyroid | Thyroid,pork | 52 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 51 | suppressed |
| Phenytoin | Phenytoin | 51 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 50 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 49 | 21 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 49 | suppressed |
| Lorazepam | Lorazepam | 49 | 12 |
| Gemfibrozil | Gemfibrozil | 48 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 47 | suppressed |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 47 | 12 |
| Calcitriol | Calcitriol | 46 | suppressed |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 46 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 46 | 17 |
| Benztropine Mesylate | Benztropine Mesylate | 45 | suppressed |
| Lacosamide | Lacosamide | 45 | suppressed |
| Linzess | Linaclotide | 45 | suppressed |
| Scopolamine | Scopolamine | 45 | suppressed |
| Xifaxan | Rifaximin | 45 | suppressed |
| Mupirocin | Mupirocin | 43 | 32 |
| Clotrimazole | Clotrimazole | 39 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 22 |
| Letrozole | Letrozole | 38 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 38 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 27 |
| Lovastatin | Lovastatin | 37 | 11 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 37 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 33 | suppressed |
| Haloperidol | Haloperidol | 32 | suppressed |
| Hydrocortisone | Hydrocortisone | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 31 | suppressed |
| Methimazole | Methimazole | 31 | suppressed |
| Novolog Flexpen | Insulin Aspart | 31 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 30 | suppressed |
| Creon | Lipase/Protease/Amylase | 29 | suppressed |
| Calcium Acetate | Calcium Acetate | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | 11 |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 27 | suppressed |
| Colchicine | Colchicine | 27 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 27 | 12 |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Telmisartan | Telmisartan | 27 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 26 | 16 |
| Ramipril | Ramipril | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 24 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 24 | suppressed |
| Isentress | Raltegravir Potassium | 23 | suppressed |
| Permethrin | Permethrin | 23 | 12 |
| Phenobarbital | Phenobarbital | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 21 | 16 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 21 | suppressed |
| Paricalcitol | Paricalcitol | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 12 |
| Nitroglycerin | Nitroglycerin | 20 | 14 |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 20 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 19 | suppressed |
| Dexamethasone | Dexamethasone | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | 12 |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Naproxen | Naproxen | 17 | 14 |
| Nystatin | Nystatin | 17 | suppressed |
| Metronidazole | Metronidazole | 16 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Triazolam | Triazolam | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Acarbose | Acarbose | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Ilevro | Nepafenac | 12 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Angeliq | Drospirenone/Estradiol | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $421.88 · 23 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, COMIRNATY, Cologuard Collection Kit, ELIQUIS, EVENITY, Jornay PM, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, UBRELVY, VRAYLAR, Wegovy, ZORYVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error